[go: up one dir, main page]

MX2024005483A - Vacunas contra influenza multivalentes que comprenden hemaglutinina recombinante y neuraminidasa y metodos para usar las mismas. - Google Patents

Vacunas contra influenza multivalentes que comprenden hemaglutinina recombinante y neuraminidasa y metodos para usar las mismas.

Info

Publication number
MX2024005483A
MX2024005483A MX2024005483A MX2024005483A MX2024005483A MX 2024005483 A MX2024005483 A MX 2024005483A MX 2024005483 A MX2024005483 A MX 2024005483A MX 2024005483 A MX2024005483 A MX 2024005483A MX 2024005483 A MX2024005483 A MX 2024005483A
Authority
MX
Mexico
Prior art keywords
methods
neuraminidase
same
influenza vaccines
recombinant hemagglutinin
Prior art date
Application number
MX2024005483A
Other languages
English (en)
Inventor
Timothy Alefantis
Mario Barro
Anthony Byers
Philippe- Alexandre GILBERT
Harold Kleanthous
Armaghan Naik
Konstantin Pugachev
William Warren
Guadalupe Cortes-Garcia
Saranya Sridhar
Thorsten Vogel
Original Assignee
Sanofi Pasteur Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Pasteur Inc filed Critical Sanofi Pasteur Inc
Publication of MX2024005483A publication Critical patent/MX2024005483A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16061—Methods of inactivation or attenuation
    • C12N2760/16062—Methods of inactivation or attenuation by genetic engineering
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

En la presente se divulgan vacunas multivalentes o composiciones inmunogénicas que comprenden una o más hemaglutininas (HA) de virus de influenza recombinantes, una o más neuraminidasas (NA) de virus de influenza recombinantes y un adyuvante opcional. También se divulgan métodos para usar la vacuna o composición inmunógena.
MX2024005483A 2021-11-05 2022-11-04 Vacunas contra influenza multivalentes que comprenden hemaglutinina recombinante y neuraminidasa y metodos para usar las mismas. MX2024005483A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163276284P 2021-11-05 2021-11-05
PCT/US2022/079274 WO2023081798A1 (en) 2021-11-05 2022-11-04 Multivalent influenza vaccines comprising recombinant hemagglutinin and neuraminidase and methods of using the same

Publications (1)

Publication Number Publication Date
MX2024005483A true MX2024005483A (es) 2024-05-22

Family

ID=84462874

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024005483A MX2024005483A (es) 2021-11-05 2022-11-04 Vacunas contra influenza multivalentes que comprenden hemaglutinina recombinante y neuraminidasa y metodos para usar las mismas.

Country Status (10)

Country Link
US (1) US20240277828A1 (es)
EP (1) EP4426346A1 (es)
JP (1) JP2024542093A (es)
KR (1) KR20240105412A (es)
CN (1) CN118201635A (es)
AU (1) AU2022379948A1 (es)
CA (1) CA3237134A1 (es)
IL (1) IL312545A (es)
MX (1) MX2024005483A (es)
WO (1) WO2023081798A1 (es)

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4270537A (en) 1979-11-19 1981-06-02 Romaine Richard A Automatic hypodermic syringe
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
CA1283827C (en) 1986-12-18 1991-05-07 Giorgio Cirelli Appliance for injection of liquid formulations
GB8704027D0 (en) 1987-02-20 1987-03-25 Owen Mumford Ltd Syringe needle combination
US4940460A (en) 1987-06-19 1990-07-10 Bioject, Inc. Patient-fillable and non-invasive hypodermic injection device assembly
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US5339163A (en) 1988-03-16 1994-08-16 Canon Kabushiki Kaisha Automatic exposure control device using plural image plane detection areas
FR2638359A1 (fr) 1988-11-03 1990-05-04 Tino Dalto Guide de seringue avec reglage de la profondeur de penetration de l'aiguille dans la peau
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5190521A (en) 1990-08-22 1993-03-02 Tecnol Medical Products, Inc. Apparatus and method for raising a skin wheal and anesthetizing skin
US5527288A (en) 1990-12-13 1996-06-18 Elan Medical Technologies Limited Intradermal drug delivery device and method for intradermal delivery of drugs
GB9118204D0 (en) 1991-08-23 1991-10-09 Weston Terence E Needle-less injector
SE9102652D0 (sv) 1991-09-13 1991-09-13 Kabi Pharmacia Ab Injection needle arrangement
US5328483A (en) 1992-02-27 1994-07-12 Jacoby Richard M Intradermal injection device with medication and needle guard
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
US5569189A (en) 1992-09-28 1996-10-29 Equidyne Systems, Inc. hypodermic jet injector
US5334144A (en) 1992-10-30 1994-08-02 Becton, Dickinson And Company Single use disposable needleless injector
US5762939A (en) 1993-09-13 1998-06-09 Mg-Pmc, Llc Method for producing influenza hemagglutinin multivalent vaccines using baculovirus
US5976552A (en) 1995-04-28 1999-11-02 Protein Sciences Corporation Virus vaccines
WO1995024176A1 (en) 1994-03-07 1995-09-14 Bioject, Inc. Ampule filling device
US5466220A (en) 1994-03-08 1995-11-14 Bioject, Inc. Drug vial mixing and transfer device
US6429199B1 (en) 1994-07-15 2002-08-06 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules for activating dendritic cells
CA2560114A1 (en) 1994-07-15 1996-02-01 The University Of Iowa Research Foundation Immunomodulatory oligonucleotides
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US5599302A (en) 1995-01-09 1997-02-04 Medi-Ject Corporation Medical injection system and method, gas spring thereof and launching device using gas spring
US5730723A (en) 1995-10-10 1998-03-24 Visionary Medical Products Corporation, Inc. Gas pressured needle-less injection device and method
US5893397A (en) 1996-01-12 1999-04-13 Bioject Inc. Medication vial/syringe liquid-transfer apparatus
GB9607549D0 (en) 1996-04-11 1996-06-12 Weston Medical Ltd Spring-powered dispensing device
WO1998037919A1 (en) 1997-02-28 1998-09-03 University Of Iowa Research Foundation USE OF NUCLEIC ACIDS CONTAINING UNMETHYLATED CpG DINUCLEOTIDE IN THE TREATMENT OF LPS-ASSOCIATED DISORDERS
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
US5993412A (en) 1997-05-19 1999-11-30 Bioject, Inc. Injection apparatus
CA2301575C (en) 1997-05-20 2003-12-23 Ottawa Civic Hospital Loeb Research Institute Vectors and methods for immunization or therapeutic protocols
IT1298087B1 (it) 1998-01-08 1999-12-20 Fiderm S R L Dispositivo per il controllo della profondita' di penetrazione di un ago, in particolare applicabile ad una siringa per iniezioni
US6218371B1 (en) 1998-04-03 2001-04-17 University Of Iowa Research Foundation Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines
EP2049564B1 (en) 2006-08-02 2017-05-17 The UAB Research Foundation Methods and compositions related to soluble monoclonal variable lymphocyte receptors of defined antigen specificity
EA022841B1 (ru) 2009-12-28 2016-03-31 ДиЭсЭм АйПи АССЕТС Б.В. Получение гетерологичных полипептидов в микроводорослях, внеклеточные микроводорослевые тельца, композиции и способы их получения и применения
CN102939102A (zh) 2010-04-09 2013-02-20 乌得勒支大学控股有限责任公司 重组多聚流感蛋白
JP5918870B2 (ja) * 2012-03-06 2016-05-18 クルセル ホランド ベー ヴェー インフルエンザに対する改善されたワクチン接種
US10130700B2 (en) * 2014-06-20 2018-11-20 The United States of America, as represented by the Secretary, DHHS Polyvalent influenza virus-like particles (VLPS) and use as vaccines
WO2016097769A1 (en) 2014-12-19 2016-06-23 Aberystwyth University A method for diagnosing lung cancer
WO2019191261A1 (en) * 2018-03-28 2019-10-03 Sanofi Pasteur Inc. Methods of generating broadly protective vaccine compositions comprising neuraminidase
JP2022552745A (ja) 2019-10-21 2022-12-19 サノフィ パスツール インコーポレイテッド ワクチンを設計するためのシステムおよび方法
CN114846560A (zh) 2019-10-21 2022-08-02 赛诺菲巴斯德股份有限公司 用于预测生物应答的系统和方法
MX2023005018A (es) 2020-10-28 2023-05-16 Sanofi Pasteur Liposomas que contienen un agonista de tlr4, preparacion y usos de los mismos.

Also Published As

Publication number Publication date
CN118201635A (zh) 2024-06-14
US20240277828A1 (en) 2024-08-22
WO2023081798A1 (en) 2023-05-11
JP2024542093A (ja) 2024-11-13
EP4426346A1 (en) 2024-09-11
CA3237134A1 (en) 2023-05-11
KR20240105412A (ko) 2024-07-05
IL312545A (en) 2024-07-01
AU2022379948A1 (en) 2024-06-20

Similar Documents

Publication Publication Date Title
MX2023000411A (es) Vacuna combinada de sars-cov-2 e influenza.
ATE499113T1 (de) Influenzavirus-impfstoffzusammensetzung
WO2019246363A8 (en) Mosaic influenza virus hemagglutinin polypeptides and uses thereof
WO2007124479A3 (en) Avian influenza viruses, vaccines, compositions, formulations, and methods
ZA202310755B (en) Immunogenic composition against influenza
WO2015195218A8 (en) Polyvalent influenza virus-like particles (vlps) and use as vaccines
AR080111A1 (es) Metodos y composiciones de inmunizacion
BR112012022939A2 (pt) composição farmacêutica para uso em um método de imunização de um indivíduo em necessidade do mesmo contra um vírus influenza
MX2018015506A (es) Vacuna contra virus de bronquitis infecciosa.
BR112023021812A2 (pt) Composição vacinal adjuvantada e métodos
MX2023000884A (es) Vacuna que usa vectores de influenza deficientes en m2/bm2.
NZ739260A (en) Inactivated canine influenza vaccines and methods of making and uses thereof
MX2024005482A (es) Vacunas hibridas multivalentes antigripales que comprenden hemaglutinina y neuraminidasa y metodos de uso de las mismas.
PH12018502436A1 (en) Multivalent vaccines major swine viral diseases
MX2021011913A (es) Composiciones de virus inactivado y formulaciones de vacunas contra el zika.
MX2019012620A (es) Composiciones de vacunas.
MX2024005483A (es) Vacunas contra influenza multivalentes que comprenden hemaglutinina recombinante y neuraminidasa y metodos para usar las mismas.
ZA202400113B (en) Adjuvanted inactivated recombinant rabies virus vectored coronavirus vaccine formulations
MY153290A (en) Multivalent avian influenza vaccines
MX2024004252A (es) Vacunas antigripales multivalentes.
BR112022019207A2 (pt) Composições de vacina para coronavírus e métodos de uso das mesmas
MX2024003337A (es) Composiciones inmunogenicas contra la influenza.
PE20212322A1 (es) Vacuna de influenza atenuada en vivo composicion y proceso de preparacion de los mismos
WO2008115785A3 (en) Multivalent avian influenza vaccines and methods
AR114410A1 (es) Vacuna multivalente contra influenza viva atenuada para prevenir y controlar el virus influenza equino (vie) en caballos